Grossman S. Adam's most recent trade in Adma Biologics Inc was a trade of 15,000 Common Stock done at an average price of $20.8 . Disclosure was reported to the exchange on June 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 16 Jun 2025 | 15,000 | 2,049,850 (2%) | 0% | 20.8 | 312,150 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 15,000 | 810,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 16 Jun 2025 | 15,000 | 2,064,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 16 Jun 2025 | 6,000 | 2,043,850 (2%) | 0% | 20.8 | 124,860 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 15 May 2025 | 15,000 | 2,070,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 15,000 | 825,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.45 per share. | 15 May 2025 | 15,000 | 2,055,850 (2%) | 0% | 19.5 | 291,750 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.45 per share. | 15 May 2025 | 6,000 | 2,049,850 (2%) | 0% | 19.5 | 116,700 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2025 | 15,000 | 840,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.46 per share. | 15 Apr 2025 | 15,000 | 2,061,850 (2%) | 0% | 21.5 | 321,900 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 15 Apr 2025 | 15,000 | 2,076,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.46 per share. | 15 Apr 2025 | 6,000 | 2,055,850 (2%) | 0% | 21.5 | 128,760 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 19 Mar 2025 | 15,000 | 2,082,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2025 | 15,000 | 855,950 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 18.92 per share. | 19 Mar 2025 | 15,000 | 2,067,850 (2%) | 0% | 18.9 | 283,800 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 18.92 per share. | 19 Mar 2025 | 6,000 | 2,061,850 (2%) | 0% | 18.9 | 113,520 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.91 per share. | 06 Mar 2025 | 56,438 | 2,097,363 (2%) | 0% | 16.9 | 954,367 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.02 per share. | 06 Mar 2025 | 29,513 | 2,067,850 (2%) | 0% | 17.0 | 502,311 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.78 per share. | 25 Feb 2025 | 54,867 | 2,153,801 (2%) | 0% | 15.8 | 865,801 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.44 per share. | 25 Feb 2025 | 18,018 | 2,208,668 (2%) | 0% | 15.4 | 278,198 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 376,744 | 376,744 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 252,022 | 2,226,686 (2%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.15 per share. | 31 Dec 2024 | 14,343 | 1,974,664 (2%) | 0% | 17.1 | 245,982 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.10 per share. | 22 Nov 2024 | 48,967 | 1,989,007 (2%) | 0% | 21.1 | 1,033,204 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.99 per share. | 30 Sep 2024 | 21,752 | 2,037,974 (2%) | 0% | 20.0 | 434,822 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.29 per share. | 26 Aug 2024 | 389,356 | 2,059,726 (2%) | 0% | 17.3 | 6,732,900 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 341,960 | 741,020 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.35 per share. | 26 Aug 2024 | 341,960 | 2,401,686 (2%) | 0% | 3.4 | 1,145,566 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.69 per share. | 26 Aug 2024 | 236,889 | 2,059,726 (2%) | 0% | 17.7 | 4,191,088 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.35 per share. | 26 Aug 2024 | 64,405 | 2,124,131 (2%) | 0% | 3.4 | 215,757 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 64,405 | 1,082,980 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 60,000 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.80 per share. | 26 Aug 2024 | 60,000 | 2,296,615 (2%) | 0% | 10.8 | 648,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 55,000 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 26 Aug 2024 | 55,000 | 2,179,131 (2%) | 0% | 5 | 275,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 47,396 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.91 per share. | 26 Aug 2024 | 47,396 | 2,449,082 (2%) | 0% | 2.9 | 138,159 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 40,500 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.37 per share. | 26 Aug 2024 | 40,500 | 2,236,615 (2%) | 0% | 9.4 | 379,485 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 16,984 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.96 per share. | 26 Aug 2024 | 16,984 | 2,196,115 (2%) | 0% | 6.0 | 101,225 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.18 per share. | 30 Jun 2024 | 21,752 | 2,059,726 (2%) | 0% | 11.2 | 243,187 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Other type of transaction at price $ 3.21 per share. | 14 Jun 2024 | 460,000 | 2,191,475 (2%) | 0% | 3.2 | 1,476,600 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Sale of securities on an exchange or to another person at price $ 10.72 per share. | 14 Jun 2024 | 100,000 | 2,081,475 (2%) | 0% | 10.7 | 1,071,980 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Jun 2024 | 10,000 | 2,181,475 (2%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.60 per share. | 31 Mar 2024 | 21,752 | 2,651,475 (3%) | 0% | 6.6 | 143,563 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 06 Mar 2024 | 55,003 | 2,701,990 (3%) | 0% | 6.1 | 336,618 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.16 per share. | 06 Mar 2024 | 28,763 | 2,673,227 (3%) | 0% | 6.2 | 177,180 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.36 per share. | 29 Feb 2024 | 9,588 | 2,756,993 (3%) | 0% | 5.4 | 51,392 | Common Stock |
| Adma Biologics Inc | S. Adam Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 870,950 | 870,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Grossman S. Adam | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 557,728 | 2,766,581 (3%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Grossman S. Adam | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.26 per share. | 25 Feb 2024 | 22,457 | 2,208,853 (2%) | 0% | 5.3 | 118,124 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.52 per share. | 31 Dec 2023 | 23,057 | 2,231,310 (2%) | 0% | 4.5 | 104,218 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.61 per share. | 15 Aug 2023 | 1,589,987 | 2,523,088 (2%) | 1% | 4.6 | 7,329,840 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 583,224 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.66 per share. | 15 Aug 2023 | 583,224 | 4,623,544 (5%) | 0% | 3.7 | 2,134,600 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.54 per share. | 15 Aug 2023 | 510,469 | 4,113,075 (4%) | 0% | 4.5 | 2,318,959 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 400,000 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 15 Aug 2023 | 400,000 | 3,690,320 (4%) | 0% | 3.2 | 1,288,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 350,000 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.71 per share. | 15 Aug 2023 | 350,000 | 4,040,320 (4%) | 0% | 3.7 | 1,298,500 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 277,604 | 47,396 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.92 per share. | 15 Aug 2023 | 277,604 | 3,290,320 (3%) | 0% | 2.9 | 809,216 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.35 per share. | 15 Aug 2023 | 277,131 | 3,012,716 (3%) | 0% | 2.4 | 651,258 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 277,131 | 181,569 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 212,500 | 387,500 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.67 per share. | 15 Aug 2023 | 212,500 | 2,735,585 (3%) | 0% | 1.7 | 354,875 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.33 per share. | 15 Aug 2023 | 3 | 2,523,085 (2%) | 0% | 4.3 | 13 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.69 per share. | 30 Jun 2023 | 20,051 | 2,523,085 (2%) | 0% | 3.7 | 73,988 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.31 per share. | 31 Mar 2023 | 17,853 | 2,543,139 (2%) | 0% | 3.3 | 59,093 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 1,147,385 | 1,147,385 | - | - | Employee Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 573,695 | 2,584,599 (2%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 25 Feb 2023 | 23,607 | 2,560,992 (2%) | 0% | 3.4 | 80,264 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.42 per share. | 25 Feb 2023 | 14,412 | 2,018,411 (2%) | 0% | 3.4 | 49,289 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 25 Feb 2023 | 7,507 | 2,010,904 (2%) | 0% | 3.6 | 26,650 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.42 per share. | 25 Feb 2023 | 4,018 | 2,032,823 (2%) | 0% | 3.4 | 13,742 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.87 per share. | 04 Jan 2023 | 166,867 | 2,036,841 (2%) | 0% | 3.9 | 645,775 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.43 per share. | 30 Sep 2022 | 101,315 | 2,188,725 (2%) | 0% | 2.4 | 246,195 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.46 per share. | 23 Mar 2022 | 50,539 | 2,360,044 (2%) | 0% | 1.5 | 73,787 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 600,000 | 600,000 | - | - | Employee Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 300,000 | 2,410,583 (2%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.00 per share. | 25 Oct 2021 | 250,000 | 1,128,444 (1%) | 0% | 1 | 250,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.00 per share. | 25 Oct 2021 | 100,000 | 2,137,616 (2%) | 0% | 1 | 100,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 458,700 | 458,700 | - | - | Employee Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 221,447 | 397,545 (0%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 2.24 per share. | 08 Sep 2020 | 4,000 | 176,098 (0%) | 0% | 2.2 | 8,960 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.07 per share. | 10 Aug 2020 | 2,990 | 169,098 (0%) | 0% | 3.1 | 9,179 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.04 per share. | 10 Aug 2020 | 2,000 | 171,098 (0%) | 0% | 3.0 | 6,080 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 2.97 per share. | 10 Aug 2020 | 1,000 | 172,098 (0%) | 0% | 3.0 | 2,970 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.10 per share. | 10 Aug 2020 | 10 | 166,108 (0%) | 0% | 3.1 | 31 | Common Stock |